Effect of bortezomib on the drug sensitivity of imatinib resistant K562/G01 cells.
- Author:
Ying ZHOU
1
;
Liang-Ming MA
;
Xiao-Yu LI
;
Hua-Ping ZHANG
;
Tao WANG
;
Yan-Yan NIU
;
Rui-Rui REN
Author Information
- Publication Type:Journal Article
- MeSH: ATP Binding Cassette Transporter, Sub-Family B; ATP-Binding Cassette, Sub-Family B, Member 1; genetics; Antineoplastic Agents; pharmacology; Benzamides; Boronic Acids; pharmacology; Bortezomib; Cell Cycle; Cell Cycle Checkpoints; Cyclooxygenase 2; genetics; Drug Resistance, Neoplasm; drug effects; Humans; Imatinib Mesylate; K562 Cells; Piperazines; pharmacology; Pyrazines; pharmacology; Pyrimidines; pharmacology
- From: Chinese Journal of Hematology 2011;32(6):392-395
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo explore the effect of bortezomib (BOR) on the drug sensitivity of imatinib-resistant chronic myeloid leukemia cell line K562/G01 cell and its mechanism.
METHODSMTT assay was used to detect the inhibition effect of cell growth, flow cytometry to cell cycle, and real time-PCR to the expression of COX-2 and mdr1 mRNA.
RESULTSCombination of 10 and 20 nmol/L BOR with imatinib could significantly enhance the sensitivity of K562/G01 to imatinib, the reverse factor was 1.83 and 2.72-fold respectively. Cell cycle arrested at G(2)/M phase could be observed by flow cytometry on BOR treatment. The over-expression of COX-2 and mdr1 could be down-regulated by BOR.
CONCLUSIONSBOR can enhance the imatinib sensitivity of imatinib resistant K562/G01 cell. The mechanism may be related to cell cycle phase arrested at G2/M and down-regulation of COX-2 and mdr1 expression.
